Annemiek M.C. Gennissen

Medicine · Health Sciences

7h-index764citations70works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(42), Chromatin Remodeling and Cancer(21), Peptidase Inhibition and Analysis(17), Renal cell carcinoma treatment(10), Signaling Pathways in Disease(10)

Publications70 total

Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Figure from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Figure from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2023Open Access
Supplemental Table S2 and Table S3 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S1 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Figure S4 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
2023Open Access
Table S3 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
2023Open Access
Figure S1 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
2023Open Access
Supplemental Table S1 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Figure S6 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
2023Open Access
Figure S2 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
2023Open Access
Supplemental figure legends from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplementary figures and tables legends from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Katrien Berns(44), E. Marielle Hijmans(44), René Bernards(44), Steven de Jong(29), G. Bea A. Wisman(28), Joseph J. Caumanns(24), Hiroaki Itamochi(24), Gert Jan Meersma(23), Roderick L. Beijersbergen(22), Rudolf S.N. Fehrmann(22), Tushar Tomar(22), Harry Klip(22), Evelien W. Duiker(22), Desirée Weening(22), Anna K.L. Reyners(22), Michael J. Birrer(22), Helga B. Salvesen(22), Els Van Nieuwenhuysen(22), James D. Brenton(22), Elena Ioana Braicu(22)